Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: Results of a phase I-II randomized clinical trial

Journal of Infectious Diseases

Volumn 198, Issue 9, 2008, Pages 1309-1316

  Keitel, Wendy A ^a   Campbell, James D ^b   Treanor, John J ^d   Walter, Emmanuel B ^e   Patel, Shital M ^a   He, Fenhua ^c   Noah, Diana L ^f   Hill, Heather ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c EMMES CORPORATION   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED;

EID: 54249154153     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592172     Document Type: Article

References (25)

1. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med 2006; 354:1343-51.
2. Keitel WA, Couch RB, Cate TR, et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994; 32:2468-73.
3. Keitel W, Atmar R. Preparing for a possible pandemic; influenza A/H5N1 vaccine development. Curr Opin Pharmacol 2007; 7:484-90.
4. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17:99-104.
5. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163-71.
6. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
7. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza (H5N1) vaccine in adults. J Infect Dis 2008; 197:667-75.
8. Nolan T, Richmond P, Papanoum K, et al. Phase I and II trials of a prototype adjuvanted inactivated split-virion influenza A/Vietnam/ 1194/2004NIBRG (H5N1) vaccine (abstract P726). In: Program and abstracts of the Options for the Control of Influenza VI Conference; 17-23 June 2007; Toronto, Canada.
9. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-7.
10. Vajo Z, Kosa L, Visontay I, et al. Inactivated whole virus influenza A (H5N1) vaccine. Emerg Infect Dis 2007; 13:807-8.
11. Keitel W, Dekker C, Mink C, Campbell J, Edwards K, Patel S. A phase I, randomized, double-blind, placebo-controlled dose ranging clinical trial of the safety, reactogenicity and immunogenicity of immunization with inactivated Vero cell culture-derived influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy young adults (abstract S2). In: Program and abstracts of the 11th Annual Conference on Vaccine Research; 5-7 May 2008; Baltimore, MD.
12. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Clinical data needed to support the licensure of pandemic influenza vaccines: guidance for industry, 1-18. 2007. Available at: http://www.fda.gov/cber/gdlns/panfluvac.pdf. Accessed 2 September 2008.
13. Hennessy AV, Davenport FM. Studies on vaccination of infants against influenza with influenza hemagglutinin. Proc Soc Exp Biol Med 1974; 146:200-4.
14. 4 on purified influenza virus hemagglutinins in man. J Immunol 1968; 100:1139-40.
15. 3 adsorbed Tween-ether split product influenza vaccine in young adults 1979. Infection 1981; 9:85.
16. Pressler K, Peukert M, Schenk D, Borgono M. Comparison of the antigenicity and tolerance of an influenza aluminium oxide adsorbate vaccine with an aqueous vaccine. Pharmatherapeutica 1982; 3:195-200.
17. Potter CW. Inactivated influenza virus vaccine. In: Beare AS, ed. Basic and applied influenza research. Boca Raton: CRC Press, 1982; 119-58.
18. Nicholson KG, Tyrrell DA, Harrison P, et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 1979; 7:123-36.
19. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective in a mouse model. Vaccine 2007; 25:3554-60.
20. Brady RC, Treanor JJ, Atmar RL, Chen WH, Winokur P, Belshe R. A phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy elderly adults (abstract P739). In: Program and abstracts of the Options for the Control of Influenza VI Conference; 17-23 June 2007; Toronto, Canada.
21. Treanor J, Bernstein D, Edwards K, Zangwill K, Noah D. Evaluation of inactivated monovalent rga/Vietnam/1203/04 X PR8 subvirion vaccine in healthy elderly adults (abstract P731). In: Program and abstracts of the Options for the Control of Influenza VI Conference; 17-23 June 2007; Toronto, Canada.
22. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
23. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006; 43:1135-42.
24. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 2007; 370:580-9.
25. Hem SL, HogenEsch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007; 6:685-98.